# Annovis Bio (ANVS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ANVS
## Company Profile
- Ticker: ANVS
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 1.8 USD
- Market cap: 79127874.48 USD
- Last updated: 2026-08-12
## Business Overview
### Phase 3 Neurodegenerative Disease Company
Annovis Bio is developing buntanetap, an oral candidate for Alzheimer’s disease and Parkinson’s disease. Through an RNA-targeting mechanism, buntanetap is designed to reduce translation of multiple neurotoxic proteins, including APP/amyloid beta, tau, alpha-synuclein, and TDP-43.
### Registrational Alzheimer’s Study
The pivotal Phase 3 Alzheimer’s study enrolls patients with early disease and a positive plasma pTau217 biomarker. The design evaluates symptomatic improvement at six months and a potential disease-modifying effect over 18 months.
### Biomarker-Enabled Development
Annovis is incorporating plasma pTau217, skin-biopsy alpha-synuclein, and digital motor assessments across its programs. These tools are intended to enrich patient selection and connect clinical outcomes with evidence of underlying disease biology.
### One Oral Asset Across Two Diseases
Buntanetap is being developed as a once-daily oral therapy across both Alzheimer’s and Parkinson’s disease. A shared mechanism and manufacturing base allow Annovis to pursue two large neurodegenerative indications while using disease-specific clinical endpoints and biomarkers.
### Long-Term Parkinson’s Study
An open-label extension study in Parkinson’s disease is assessing safety and efficacy over 36 months. It incorporates skin-biopsy alpha-synuclein biomarkers and NeuroRPM artificial intelligence-based digital measures to track changes in motor function.
## Why The Stock Is Moving

As of Aug 12, 2026, ANVS closed down 4.76% at $1.80. No new same-company headline was identified in the current news window.

## Future Catalysts

- Randomization in the Alzheimer’s Phase 3 study is expected to be completed in summer 2026, with initial topline results anticipated in early 2027.
- An NDA for buntanetap as a symptomatic Alzheimer’s treatment is expected in early 2027, followed by a potential disease-modifying treatment submission in early 2028.
- Enrollment in the Parkinson’s open-label extension study is expected to be completed in the fourth quarter of 2026.

## Recent News
- 2026-07-07 11:00 EST — [Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease](https://biopharmsignal.com/news/ANVS/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-35d9e2ee) — Source: Annovis Bio
- 2026-07-01 12:00 EST — [Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer](https://biopharmsignal.com/news/ANVS/annovis-appoints-cheng-fang-ph-d-as-chief-scientific-officer-56e8ee3d) — Source: Annovis Bio
- 2026-05-26 12:00 EST — [Annovis Bio Regains NYSE Listing Compliance](https://biopharmsignal.com/news/ANVS/annovis-bio-regains-nyse-listing-compliance-d6911038) — Source: Annovis Bio
- 2026-05-20 12:00 EST — [Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants](https://biopharmsignal.com/news/ANVS/annovis-announces-pricing-of-15-0-million-public-offering-of-common-stock-and-ac-b755aa8d) — Source: Annovis Bio
- 2026-05-19 20:06 EST — [Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants](https://biopharmsignal.com/news/ANVS/annovis-announces-launch-of-proposed-public-offering-of-common-stock-and-accompa-8ec0d147) — Source: Annovis Bio